Featured 13F manager
Opaleye Management Inc. James Silverman
Boston, MA 23 processed 13Fs on this site · 2021 Q3–2026 Q2
- $1.1B
- 58 Positions
- 2026 Q2
- +45.5% QoQ
- Top 5 46.8%
James Silverman files Opaleye Management Inc. as a Form 13F. The latest book is 2026 Q2 at $1.1B, up 45.5% QoQ, led by Liquidia, Eton Pharmaceuticals, and Harrow.
Portfolio
top 5 46.8% · top 10 64.8%
- LQDA - Liquidia 17.7%
- ETON - Eton Pharmaceuticals 9.4%
- HROW - Harrow 9.2%
- IRON - Disc Medicine 5.7%
- URGN - Urogen Pharma 4.8%
- APGE - Apogee Therapeutics 4.7%
- MGTX - Meiragtx 4.3%
- SLGL - Sol-Gel Technologies 3.3%
- RZLT - Rezolute 3.0%
- TGTX - Tg Therapeutics 2.7%
- IMMX - Immix Biopharma 2.2%
- CBIO - Crescent Biopharma 2.1%
- Other 30.9%
AUM over time
Book
| HROW - Harrow Health | 23.92% | Hold | 3,775,000 | $21.16 | $80M | — | — |
| OCUL - Ocular Therapeutix | 9.64% | Add +0.5% | 6,105,900 | $5.27 | $32M | +30,900 | +$15M |
| TELA - Tela Bio | 6.61% | Hold | 2,072,813 | $10.64 | $22M | — | — |
| RYTM - Rhythm Pharmaceuticals | 3.93% | Hold | 735,000 | $17.84 | $13M | — | — |
| CRNX - Crinetics Pharmaceuticals | 3.78% | Add +7.3% | 785,794 | $16.06 | $13M | +53,794 | −$773K |
| Karyopharm Therapeutics | 3.27% | Add +132.9% | 2,810,800 | $3.89 | $11M | +1,603,959 | +$7M |
| Keros Therapeutics | 3.04% | Hold | 238,000 | $42.70 | $10M | — | — |
| Tracon Pharmaceuticals | 2.70% | Add +3.8% | 4,764,508 | $1.89 | $9M | +174,508 | +$2M |
| ETON - Eton Pharmaceuticals | 2.52% | Add +0.7% | 2,185,000 | $3.85 | $8M | +15,000 | +$2M |
| Protara Therapeutics | 2.42% | Hold | 2,692,594 | $3.00 | $8M | — | — |
| BHVN - Biohaven | 2.21% | Hold | 540,000 | $13.66 | $7M | — | — |
| CYTK - Cytokinetics | 2.19% | Reduce −17.0% | 207,500 | $35.19 | $7M | −42,500 | −$4M |
| Kalvista Pharmaceuticals | 2.17% | Hold | 923,200 | $7.86 | $7M | — | — |
| PCVX - Vaxcyte | 1.99% | Hold | 177,000 | $37.48 | $7M | — | — |
| LRMR - Larimar Therapeutics | 1.90% | Reduce −10.2% | 1,401,000 | $4.53 | $6M | −159,000 | −$96K |
| Theravance Biopharma | 1.78% | Add +523.6% | 546,304 | $10.85 | $6M | +458,704 | +$5M |
| ARQT - Arcutis Biotherapeutics | 1.65% | New | 502,000 | $11.00 | $6M | +502,000 | +$6M |
| FDMT - 4D Molecular Therapeutics | 1.62% | Reduce −4.8% | 314,000 | $17.19 | $5M | −16,000 | −$2M |
| Jounce Therapeutics | 1.60% | New | 2,880,000 | $1.85 | $5M | +2,880,000 | +$5M |
| Marinus Pharmaceuticals | 1.58% | Reduce −7.4% | 765,000 | $6.90 | $5M | −61,200 | +$2M |
| XOMA - XOMA Del | 1.54% | Hold | 243,000 | $21.11 | $5M | — | — |
| EWTX - Edgewise Therapeutics | 1.50% | Add +22.7% | 750,000 | $6.67 | $5M | +138,600 | −$463K |
| Morphosys AG | 1.42% | Add +33.2% | 1,194,000 | $3.96 | $5M | +297,400 | +$2M |
| IDYA - Ideaya Biosciences | 1.41% | Add +147.1% | 343,000 | $13.73 | $5M | +204,200 | +$2M |
| URGN - Urogen Pharma | 1.40% | Add +3.3% | 505,000 | $9.24 | $5M | +16,344 | +$332K |
| Theseus Pharmaceuticals | 1.30% | Reduce −8.8% | 488,100 | $8.88 | $4M | −46,900 | +$2M |
| Edap Tms S A | 1.27% | Add +24.7% | 382,400 | $11.07 | $4M | +75,687 | +$964K |
| CATBUSD - Astria Therapeutics | 1.23% | Add +15.4% | 302,000 | $13.56 | $4M | +40,297 | +$200K |
| LQDA - Liquidia | 1.19% | Add +2.7% | 575,200 | $6.91 | $4M | +15,200 | +$407K |
| Fortress Biotech | 1.12% | Add +123.1% | 4,573,600 | $0.8200 | $4M | +2,523,600 | +$2M |
| PHAT - Phathom Pharmaceuticals | 1.06% | Add +18.8% | 496,000 | $7.14 | $4M | +78,500 | −$1M |
| CDXS - Codexis | 0.93% | Reduce −21.7% | 750,000 | $4.14 | $3M | −207,500 | −$1M |
| IOVA - Iovance Biotherapeutics | 0.77% | New | 421,000 | $6.11 | $3M | +421,000 | +$3M |
| Relay Therapeutics | 0.62% | New | 125,500 | $16.47 | $2M | +125,500 | +$2M |
| Kezar Life Sciences | 0.59% | New | 625,000 | $3.13 | $2M | +625,000 | +$2M |
| MLYS - Mineralys Therapeutics | 0.54% | New | 115,000 | $15.66 | $2M | +115,000 | +$2M |
| STXS - Stereotaxis | 0.53% | Reduce −26.8% | 867,100 | $2.04 | $2M | −317,900 | −$684K |
| TRVI - Trevi Therapeutics | 0.46% | Add +72.3% | 835,800 | $1.85 | $2M | +350,800 | +$610K |
| PRQR - Proqr Therapeutics | 0.42% | Reduce −55.3% | 653,000 | $2.13 | $1M | −807,000 | −$4M |
| Nyxoah S A | 0.13% | New | 57,585 | $7.47 | $430K | +57,585 | +$430K |
| Modular Medical | 0.08% | Reduce −25.1% | 183,500 | $1.45 | $266K | −61,500 | −$224K |
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ZNTL - Zentalis Pharmaceuticals | 1.17% | Exit | 0 | $20.14 | $3M | −167,500 | −$3M |
| WHWK - Aadi Bioscience | 1.12% | Exit | 0 | $12.83 | $3M | −252,046 | −$3M |
| Mersana Therapeutics | 0.94% | Exit | 0 | $5.86 | $3M | −460,000 | −$3M |
| Fennec Pharmaceuticals | 0.91% | Exit | 0 | $9.60 | $3M | −272,200 | −$3M |
| BCABGBP - Bioatla | 0.75% | Exit | 0 | $8.25 | $2M | −261,800 | −$2M |
| Allakos | 0.45% | Exit | 0 | $8.42 | $1M | −153,500 | −$1M |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 58 | $1.1B | +45.5% | 13F-HR | 8/14/2026 | 000142050626001803 |
| 2026 Q1 | 54 | $759M | +0.1% | 13F-HR | 5/15/2026 | 000142050626001151 |
| 2025 Q4 | 54 | $758M | — | RESTATEMENT | 4/13/2026 | 000149315226016299 |
| 2025 Q4 | 54 | $758M | +7.2% | 13F-HR | 2/17/2026 | 000149315226007085 |
| 2025 Q3 | 43 | $707M | +41.7% | 13F-HR | 11/14/2025 | 000149315225023429 |
| 2025 Q2 | 41 | $494M | — | RESTATEMENT | 8/15/2025 | 000164117225024301 |
| 2025 Q2 | 41 | $499M | +11.1% | 13F-HR | 8/14/2025 | 000164117225023977 |
| 2025 Q1 | 45 | $449M | −21.4% | 13F-HR | 5/15/2025 | 000164117225010914 |
| 2024 Q4 | 39 | $571M | −4.8% | 13F-HR | 2/14/2025 | 000149315225006852 |
| 2024 Q3 | 44 | $600M | +37.0% | 13F-HR | 11/14/2024 | 000149315224045811 |
| 2024 Q2 | 51 | $438M | +0.2% | 13F-HR | 8/14/2024 | 000149315224032150 |
| 2024 Q1 | 52 | $459M | — | RESTATEMENT | 5/29/2024 | 000149315224021780 |
| 2024 Q1 | 51 | $437M | +16.2% | 13F-HR | 5/15/2024 | 000149315224019869 |
| 2023 Q4 | 47 | $376M | +22.5% | 13F-HR | 2/14/2024 | 000149315224006653 |
| 2023 Q3 | 41 | $307M | −26.6% | 13F-HR | 11/15/2023 | 000149315223041364 |
| 2023 Q2 | 47 | $418M | +25.1% | 13F-HR | 8/14/2023 | 000149315223028636 |
| 2023 Q1 | 41 | $334M | +16.0% | 13F-HR | 5/15/2023 | 000149315223016769 |
| 2022 Q4 | 40 | $288M | +19.0% | 13F-HR | 2/10/2023 | 000149315223004277 |
| 2022 Q3 | 42 | $242M | +9.0% | 13F-HR | 11/14/2022 | 000149315222032068 |
| 2022 Q2 | 47 | $222M | −31.1% | 13F-HR | 8/15/2022 | 000149315222022856 |
| 2022 Q1 | 45 | $322M | −31.6% | 13F-HR | 5/16/2022 | 000149315222013764 |
| 2021 Q4 | 39 | $471M | −12.0% | 13F-HR | 2/14/2022 | 000149315222004434 |
| 2021 Q3 | 48 | $535M | — | 13F-HR | 11/16/2021 | 000149315221028799 |
About
Opaleye Management Inc.
23 processed 13Fs on this site · 2021 Q3–2026 Q2